Regulator of G-protein signaling 18 integrates activating and inhibitory signaling in platelets

Blood

Volumn 119, Issue 16, 2012, Pages 3799-3807

  Gegenbauer, Kristina ^a   Elia, Giuliano ^a   Blanco Fernandez, Alfonso ^a   Smolenski, Albert ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CALCIUM ION; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; NITRIC OXIDE; PROSTACYCLIN; PROTEIN 14 3 3; PROTEIN 14 3 3 GAMMA; REGULATOR OF G PROTEIN SIGNALING 18; RGS PROTEIN; SERINE; THROMBIN; THROMBOXANE A2; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CONTROLLED STUDY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

EID: 84860340490     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-390369     Document Type: Article

References (44)

1. Schultess J, Danielewski O, Smolenski AP. Rap1GAP2 is a new GTPase-activating protein of Rap1 expressed in human platelets. Blood. 2005; 105(8):3185-3192.
2. Gambaryan S, Walter U, Ralph AB, Edward AD. cGMP and PKG signaling in platelets. In: Bradshaw RA, Dennis EA, eds. Handbook of Cell Signaling. 2nd Ed. San Diego, CA: Academic Press; 2009:1563-1567.
3. Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol. 2001;62(9):1153-1161. (Pubitemid 33055619)
4. Antl M, von Bruehl M-L, Eiglsperger C, et al. IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation. Blood. 2007;109(2):552-559. (Pubitemid 46105953)
5. Xie GX, Palmer PP. How regulators of G protein signaling achieve selective regulation. J Mol Biol. 2007;366(2):349-365. (Pubitemid 46136207)
6. Rowley JW, Oler A, Tolley ND, et al. Genome wide RNA-seq analysis of human and mouse platelet transcriptomes. Blood. 2011;118(14): e101-e111.
7. Signarvic RS, Cierniewska A, Stalker TJ, et al. RGS/Gi2alpha interactions modulate platelet accumulation and thrombus formation at sites of vascular injury. Blood. 2010;116(26):6092-6100.
8. Abramow-Newerly M, Roy AA, Nunn C, Chidiac P. RGS proteins have a signalling complex: Interactions between RGS proteins and GPCRs, effectors, and auxiliary proteins. Cell Signal. 2006;18(5):579-591. (Pubitemid 43113289)
9. Bansal G, Druey KM, Xie Z. R4 RGS proteins: regulation of G protein signaling and beyond. Pharmacol Ther. 2007;116(3):473-495. (Pubitemid 350116944)
10. Gagnon AW, Murray DL, Leadley RJ. Cloning and characterization of a novel regulator of G protein signalling in human platelets. Cell Signal. 2002; 14(7):595-606. (Pubitemid 34304344)
11. Nagata Y, Oda M, Nakata H, Shozaki Y, Kozasa T, Todokoro K. A novel regulator of G-protein signaling bearing GAP activity for G alpha i and G alpha q in megakaryocytes. Blood. 2001; 97(10):3051-3060.
12. Yowe D, Weich N, Prabhudas M, et al. RGS18 is a myeloerythroid lineage-specific regulator of G-protein-signaling molecule highly expressed in megakaryocytes. Biochem J. 2001;359(pt 1):109-118. (Pubitemid 32939212)
13. Park IK, Klug CA, Li K, et al. Molecular cloning and characterization of a novel regulator of G-protein signaling from mouse hematopoietic stem cells. J Biol Chem. 2001;276(2):915-923. (Pubitemid 32096509)
14. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci U S A. 1998;95(14):8070-8074. (Pubitemid 28326067)
15. Jackson S, Schoenwaelder S. Type I phosphoinositide 3-kinases: potential antithrombotic targets? Cell Mol Life Sci. 2006;63(10):1085-1090. (Pubitemid 43938996)
16. Wilker E, Yaffe MB. 14-3-3 Proteins - a focus on cancer and human disease. J Mol Cell Cardiol. 2004;37(3):633-642. (Pubitemid 39194555)
17. Mangin PH, Receveur N, Wurtz V, David T, Gachet C, Lanza F. Identification of five novel 14-3-3 isoforms interacting with the GPIb-IX complex in platelets. J Thromb Haemost. 2009;7(9): 1550-1555.
18. Hoffmeister M, Riha P, Neumuller O, Danielewski O, Schultess J, Smolenski AP. Cyclic nucleotide-dependent protein kinases inhibit binding of 14-3-3 to the GTPase-activating protein Rap1GAP2 in platelets. J Biol Chem. 2008; 283(4):2297-2306.
19. Danielewski O, Schultess J, Smolenski A. The NO/cGMP pathway inhibits Rap 1 activation in human platelets via cGMP-dependent protein kinase I. Thromb Haemost. 2005;93(2):319-325. (Pubitemid 40253738)
20. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem. 1996; 68(5):850-858.
21. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem. 2003; 75(17):4646-4658. (Pubitemid 37082259)
22. Vines A, McBean GJ, Blanco-Fernandez A. A flow-cytometric method for continuous measurement of intracellular Ca2+ concentration. Cytometry Part A. 2010;77A(11):1091-1097.
23. Smolenski A, Bachmann C, Reinhard K, et al. Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J Biol Chem. 1998;273(32): 20029-20035. (Pubitemid 28377554)
24. Obenauer JC, Cantley LC, Yaffe MB. Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res. 2003;31(13):3635-3641. (Pubitemid 37442212)
25. Larkin MA, Blackshields G, Brown NP, et al. Clustal W and Clustal X version 2.0. Bioinformatics. 2007;23(21):2947-2948. (Pubitemid 350162903)
26. Tzivion G, Shen YH, Zhu J. 14-3-3 proteins; bringing new definitions to scaffolding. Oncogene. 2001;20(44):6331-6338. (Pubitemid 32977842)
27. Wheeler-Jones CP, Learmonth MP, Martin H, Aitken A. Identification of 14-3-3 proteins in human platelets: effects of synthetic peptides on protein kinase C activation. Biochem J. 1996; 315(Pt 1):41-47. (Pubitemid 26113533)
28. Johnson C, Crowther S, Stafford MJ, Campbell DG, Toth R, MacKintosh C. Bioinformatic and experimental survey of 14-3-3-binding sites. Biochem J. 2010;427(1):69-78.
29. García A, Prabhakar S, Hughan S, et al. Differential proteome analysis of TRAP-activated platelets: involvement of DOK-2 and phosphorylation of RGS proteins. Blood. 2004;103(6):2088-2095. (Pubitemid 38326224)
30. Kinoshita E, Kinoshita-Kikuta E, Takiyama K, Koike T. Phosphate-binding Tag, a new tool to visualize phosphorylated proteins. Mol Cell Proteomics. 2006;5(4):749-757.
31. Lenoci L, Duvernay M, Satchell S, DiBenedetto E, Hamm HE. Mathematical model of PAR1-mediated activation of human platelets. Mol Biosyst. 2011; 7(4):1129-1137.
32. Laroche G, Giguere PM, Roth BL, Trejo J, Siderovski DP. RNA interference screen for RGS protein specificity at muscarinic and protease-activated receptors reveals bidirectional modulation of signaling. Am J Physiol Cell Physiol. 2010; 299(3):C654-C664.
33. Yaffe MB. How do 14-3-3 proteins work? Gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS Lett. 2002;513(1):53-57. (Pubitemid 34242978)
34. Kostelecky B, Saurin AT, Purkiss A, Parker PJ, McDonald NQ. Recognition of an intra-chain tandem 14-3-3 binding site within PKCepsilon. EMBO Rep. 2009;10(9):983-989.
35. Astuti P, Boutros R, Ducommun B, Gabrielli B. Mitotic phosphorylation of Cdc25B Ser321 disrupts 14-3-3 binding to the high affinity Ser323 site. J Biol Chem. 2010;285(45):34364-34370.
36. Bulavin DV, Higashimoto Y, Demidenko ZN, et al. Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol. 2003;5(6): 545-551. (Pubitemid 36781089)
37. Abramow-Newerly M, Ming H, Chidiac P. Modulation of subfamily B/R4 RGS protein function by 14-3-3 proteins. Cell Signal. 2006;18(12):2209-2222. (Pubitemid 44636163)
38. Benzing T, Koettgen M, Johnson M, et al. Interaction of 14-3-3 protein with regulator of G protein signaling 7 is dynamically regulated by tumor necrosis factor alpha. J Biol Chem. 2002;277(36): 32954-32962. (Pubitemid 34984809)
39. Niu J, Scheschonka A, Druey KM, et al. RGS3 interacts with 14-3-3 via the N-terminal region distinct from the RGS (regulator of G-protein signalling) domain. Biochem J. 2002;365(Pt 3):677-684. (Pubitemid 34864449)
40. Ward RJ, Milligan G. A key serine for the GT-Pase-activating protein function of regulator of G protein signaling proteins is not a general target for 14-3-3 interactions. Mol Pharmacol. 2005; 68(6):1821-1830. (Pubitemid 41654364)
41. Garzon J, Rodriguez-Munoz M, Lopez-Fando A, Sanchez-Blazquez P. Activation of mu-opioid receptors transfers control of Galpha subunits to the regulator of G-protein signaling RGS9-2. J Biol Chem. 2005;280(10):8951-8960. (Pubitemid 40409587)
42. Rezabkova L, Boura E, Herman P, et al. 14-3-3 protein interacts with and affects the structure of RGS domain of regulator of G protein signaling 3 (RGS3). J Struct Biol. 2010;170(3):451-461.
43. Rezabkova L, Man P, Novak P, et al. Structural basis for the 14-3-3 protein-dependent inhibition of the regulator of G-Protein signaling 3 (RGS3) function. J Biol Chem. 2011;286:43527-43536.
44. Sethakorn N, Yau DM, Dulin NO. Noncanonical functions of RGS proteins. Cell Signal. 2010; 22(9):1274-1281.